An open label, randomized, parallel controlled trial for comparing of the efficacy of anti-fungal treatment for aspergillus infection recurrence after aspergillus globulectomy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800019990

Enrollment

Unknown

Registered

2018-12-11

Start date

2019-01-01

Completion date

Unknown

Last updated

2018-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fungal pulmonary disease

Interventions

2:anti-fungal treatment

1:Without anti-fungal treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All the following qualifications must be met: 1) Aspergillus occurs in the lungs; 2) Pathological diagnosis of aspergilloma and surgical resection; 3) Sign written informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients with invasive pulmonary aspergillosis, tuberculosis and other pulmonary diseases; 2) Women who are pregnant or breastfeeding or planning to conceive during the study period, or women who are fertile but do not use effective contraceptive methods.

Design outcomes

Primary

Measure	Time frame
Recurrence of Aspergillus infection;	—

Countries

China

Contacts

Public ContactLiang Shuo

Shanghai Pulmonary Hospital

liangshuo79@163.com+86 18021070508

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 20, 2026